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Background/aim: The aim of this study was to evaluate the clinical outcomes and identify the predictors of mortality in peritoneal
dialysis patients.
Materials and methods: Medical records of all incident peritoneal dialysis (PD) patients followed up between January 2011 and May
2019 were reviewed retrospectively. All patients were followed up until death, renal transplantation, transfer to haemodialysis or the
end of the study.
Results: A total of 242 patients were included in the study. The incidence of peritonitis was 0.18 (ranging from 0 to 14.9) episodes per
patient year. Death occurred in 28% (n: 68) of cases. Age, diabetes mellitus, malignancy and refractory heart failure were independent
risk factors for all-cause mortality according to multivariate analysis. The presence of comorbid disease and diabetes mellitus and patients
aged > 65 years were associated with increased risk of mortality and decreased patient survival. Peritonitis history was associated with
increased risk of mortality. Between peritonitis and peritonitis-free group, there was no significant difference in Kaplan-Meier curves
in terms of patient survival.
Conclusion: This is the first study to define 9-year mortality predictors in PD patients in our centre. Although peritonitis is the most
feared complication of PD, our study showed that peritonitis did not reduce patient survival.
Key words: Peritoneal dialysis, peritonitis, mortality, patient survival, technique survival

1. Introduction
The prevalence of end-stage renal disease (ESRD) is
increasing in the world [1,2]. Peritoneal dialysis (PD)
has been an alternative treatment to hemodialysis (HD)
for patients with ESRD since 1976 [3,4]. PD is a homebased treatment with many advantages; preservation of
residual renal function (RRF), hemodynamic stability,
better quality of life and cost savings [5–8]. Survival rates
with PD are better than those with HD after 3 years from
initiation [5,8,9]. Despite the advantages of PD in quality
of life compared with haemodialysis, the prevalence of
PD decreases gradually [10,11]. In our country too, total
number of PD patients is gradually decreasing over the
years [12].
Prevalent PD patients in our country as of the end of
2007 were 5307 patients and this number decreased to
3346 at the end of 2017, according to the Turkish Kidney
Registry System Reports [12,13]. The long-term benefits of
PD are still controversial [5]. Therefore, this study aimed
to report a single-center experience and long-term clinical
outcomes of PD over a 9-year period.

2. Materials and methods
2.1. Participants
This study was approved by Baskent University
Institutional Review Board (Project no: KA19/196) and
supported by Başkent University Research Fund. This
was a retrospective cohort study. All patients who were
initiated on PD at Başkent University Adana Dr. Turgut
Noyan Training and Research Hospital, in Turkey, from
January 2011 to May 2019, were included. The patients
who were younger than 18 years and the patients with a
PD history of less than 3 months were excluded from our
analysis. The follow-up of the patients was reviewed until
death, renal transplantation, transferred to HD or the end
of the study in May 2019.
2.2. Clinical procedures
A double-cuffed Curl Tenckhoff catheter (ArgyleTM
Peritoneal Dialysis Catheter Kit, Curl Catch, 2 Cuff, 62
cm) was inserted in all patients in our centre using the
laparoscopy technique by general surgeons. After a break
period, patients and their caregivers underwent a standard
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training program after catheterization. Initiation of PD
refers to the time, when the patient started to use the
PD solutions effectively to performing 2-litre exchanges
4 times per day. The patients were initiated on manual
exchanges using Y-sets and twin-bag systems. PD solutions
(Physioneal 1.36, 2.27, 3.86% (glucose), Nutrineal,
Extraneal; Baxter Healthcare, USA) were utilized in all of
PD patients. Dialysis prescription was changed according
to individual requirements determined during the followup. Continuous Ambulatory Peritoneal Dialysis (CAPD)
or Automated Peritoneal Dialysis (APD), is proposed to
patients in our institute according to the patient’s wishes
and contraindications for the respective PD modality.
Patients were asked to collect urine for 24 h from
patients with appreciable urine output for peritoneal
equilibration test and for RRF calculation. Peritoneal
transport characteristic was assessed by peritoneal
equilibration test. RRF was calculated using the average
of urea and creatinine clearance [14]. Patients were
recommended to contact their dialysis nurse and/or
nephrology doctor by telephone for any medical support.
Patients with suspected peritonitis were advised to come
to the hospital. All peritonitis patients were treated
according to the International Society for Peritoneal
Dialysis Guidelines [15].
2.3. Definitions
Anuria was defined as the absence of sufficient urine
output. The PD withdrawal due to inadequate dialysis,
infection or mechanical reasons (except death, renal
transplantation, loss to follow-up) were defined as
technique failure. [5,6]. PD-related infections were
defined as peritonitis, exit site infections, and tunnel
infections [16]. Peritonitis was diagnosed according to the
International Society for Peritoneal Dialysis Guidelines
[15], which requires at least 2 of the following: 1. Clinical
features consistent with peritonitis, i.e. abdominal pain
and/or cloudy dialysate fluid, 2. Dialysate white cell count
> 50% polymorphonuclear leukocytes, >100/μL or >0.1
× 109/L (after a waiting time of at least 2 h), 3. Positive
dialysate culture. Noninfectious complications such as
hernia, dialysate leakage, drainage disorder and ileus
were defined as mechanical complications. Technique
survival was defined as the time interval between the
date of initiation of PD and the date of withdrawal of
the catheter (except death, renal transplantation, loss to
follow-up). Patient who died for any reason under PD
was defined as the mortality group and the remaining
patients who continued PD at the end of the study period
(30 May 2019) were defined as the survival group (except
renal transplantation, transfer to HD, loss to follow-up).
Early death was defined as each death occurring in the
first 6 months of PD. Patient survival was defined as the
probability of survival of patients under PD treatment

[8,17]. In the survival analysis, the starting point was
defined as the first day of PD. Endpoint of study for each
patient was death for any reason, renal transplantation,
transfer to HD, loss to follow-up or the end of the study
in May 2019.
The patients with peritonitis history were defined as
peritonitis group and the rest were defined as nonperitonitis
group. Also, as such the patients were categorized as
diabetics group, nondiabetics group, comorbidity group
and noncomorbidity group, patients were also categorized
per age; aged <40 years, aged between 40–65 years and
aged >65 years groups.
The following data were obtained from the patient files.
2.4. Baseline demographic and clinical data
Age, sex, body mass index (BMI), systolic and diastolic
blood pressure measurements, aetiology of ESRD
(diabetes mellitus, hypertension, glomerulonephritis,
tubulointerstitial nephritis, polycystic kidney diseases,
obstructive nephropathy, amyloidosis, refractory heart
failure), the presence of comorbidities (diabetes mellitus,
hypertension, cardiovascular disease, malignancy,
tuberculosis, cerebrovascular disease, and chronic lung
disease), patients with parathyroidectomy performed,
and medication history were recorded. The mean of the
last 2 values for levels of haemoglobin, serum creatinine,
calcium, phosphorus, albumin, intact parathyroid
hormone, transferrin saturation, ferritin, C-reactive
protein, total cholesterol, LDL-cholesterol, triglyceride
values and hepatitis serology were recorded. Previous
HD history, PD modality (CAPD or APD), ultrafiltration
volume, use of Icodextrin and Nutrineal dialysate, and
peritoneal transport characteristic were recorded. Daily
urine volume, Kt/V urea, and RRF of patients at the onset
of PD and at the last control or at the 12-month evaluation
before their death were recorded.
2.5. PD outcomes
Follow-up duration, dialysis duration, technique failure
rate, technique survival, PD-related infections, (Peritonitis
episodes, tunnel infection, exit-site of infection),
mechanical complications, mortality rate and patient
survival were reviewed for all patients at the end of the
study.
2.6. Subgroups
Patients were divided into different subgroups as follows;
group excluding early deaths, group excluding patients
with prior HD history, diabetics vs. nondiabetics group,
peritonitis vs. nonperitonitis group, comorbidity group,
noncomorbidity group and patients aged <40 years vs.
aged between 40–65 years, and aged > 65 years groups.
2.7. Statistical analysis
Statistical analysis was performed using the statistical
package SPSS software version 23.0 (IBM Corp., Armonk,
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NY, USA). For each continuous variable, normality
was checked by Kolmogorov–Smirnov and Shapiro–
Wilk tests and by histograms. All numerical data are
expressed as median values (minimum–maximum)
or as proportions. Comparisons between groups were
applied using student t test for normally distributed data
and Mann–Whitney U test were used for the data not
normally distributed. The categorical variables between
the groups were analysed by using the chi- square test.
Overall survival time was defined as the years elapsed
between the first day of PD and death for any reason, renal
transplantation, transfer to HD, loss to follow-up or the
end of the study in May 2019. Overall survival was analysed
using the Wald test, and the log-rank test was used to
examine their relationship when different parameters were
applied. The survival curve was plotted using the standard
Kaplan-Meier methodology. A Cox regression model
with stepwise selection was done to identify variables.
Thereafter, the treatment effect adjusted for these selected
variables was calculated. The Cox model was also used to
examine the interaction of treatment effect with subgroup

status in an exploratory analysis. Differences in the best
overall response rates between the treatment groups were
analysed with the Cochran-Mantel-Haenszel test.
3. Results
3.1. Demographic and clinical results
A total of 242 patients were included in the study. The mean
age of incident patients was 52.5 ± 16.6 years at the onset
of PD. Amongst the patients 59 of them (24.4%) were aged
>65 years and 55 of them (22.7%) were aged <40 years, and
115 of them (47.5%) were male. Diabetic nephropathy was
present in 30.2% of all patients. The PD modality was APD
in 31.4% of patients. The patients’ baseline demographic
and clinical characteristics, medication history and
biochemical parameters, and peritoneal dialysis related
data were presented in Table 1, in Table 2, and in Table 3,
respectively.
3.2. PD outcomes
Total number of our PD patients was 78 at the starting
date of the study. At the end of the study; a total of 242

Table 1. Baseline demographic and clinical characteristics of the peritoneal dialysis patients.
Mortality group
(n: 68)

Survival group
(n: 174)

Total
(n: 242)

P

Age (years)**

58.9 ± 15.8

47.6 ± 15.6

52.5 ± 16.6

0.001#

Sex (male)*

49 (46.2)

66 (48.5)

115 (47.5)

0.410

BMI (kg/m2) **

27.8 ± 6.1

27.7 ± 5.3

27.7± 5.7

0.920

Systolic BP (mmHg)**

117.6 ± 22.6

125.8 ± 22.4

122 ± 23

0.006#

Diastolic BP (mmHg)**

69.5 ± 11.1

72.7 ± 10.0

71 ± 11

0.018#

Diabetes mellitus*

48 (45.3)

25 (18.4)

73 (30.2)

0.000#

Hypertension*

24 (22.6)

45 (33.1)

69 (28.5)

0.192

Glomerulonephritis*

2 (1.9)

23 (16.9)

25 (10.3)

0.033#

TIN*

9 (8.5)

6 (4.4)

15 (6.2)

0.011#

PCKD*

3 (2.8)

10 (7.4)

13 (5.4)

0.924

Obstructive nephropathy*

1 (0.9)

6 (4.4)

7 (2.9)

0.690

Amyloidosis*

0 (0)

2 (1.5)

2 (0.8)

0.920

Refractory heart failure*

8 (7.5)

2 (1.5)

10 (4.1)

0.000#

Unknown*

9 (8.5)

16 (11.8)

25 (10.3)

0.487

Comorbidity*

93 (87.7)

86 (63.2)

179 (74)

0.000#

Malignancy*

9 (8.5)

2 (1.5)

11 (4.5)

0.000#

Tuberculosis*

4 (3.8)

6 (4.4)

10 (4.1)

0.619

CVD*

4 (3.8)

1 (0.7)

5 (2.1)

0.000#

Parathyroidectomy*

12 (11.3)

12 (8.8)

24 (10)

0.330

Etiology of ESRD

BMI: body mass index, BP: blood pressure, ESRD: End-stage renal disease, TIN: Tubulointerstitial nephritis, PCKD:
Polycystic kidney diseases, CVD: Cerebrovascular disease, # P < 0.05, *n (%), **mean ± SD
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Table 2. Patients’ medication histories and biochemical parameters.
Mortality group
(n: 68)

Survival group
(n: 174)

Total
(n:242)

P

Erythropoietin*

66 (62.3)

92 (67.6)

158 (65.3)

0.230

Iron*

70 (60.6)

104(76.5)

174 (66)

0.100

Vitamin D*

92 (53.8)

57 (67.6)

149 (61.6)

0.090

Hb (g/dL) **

10.5 ± 1.7

10.5 ± 1.4

10.5 ± 1.5

0.732

Cr (mg/dL) **

7.8 ± 2.4

9 ± 3.4

8.5 ± 3.1

0.005#

Ca (mg/dL)**

8.46 ± 0.82

8.55 ± 0.82

8.51 ± 0.82

0.389

P (mg/dL) **

4.63 ± 1.23

4.85 ± 1.21

4.75 ± 1.22

0.170

Alb (g/L)**

3.18 ± 0.45

3.52 ± 0.41

3.3 ± 0.4

0.001#

PTH (pg/mL)**

469 ± 396

495 ± 434

484 ± 417

0.621

T. Sat %, **

28 ± 18

32 ± 16

30 ± 17

0.091

Fer, ng/mL**

667 ± 592

556 ± 519

605 ± 554

0.124

CRP, mg/L**

34 ± 41

19 ± 30

26 ± 36

0.000#

TC, mg/dL**

186 ± 47

193 ± 42

190 ± 45

0.093

LDL, mg/dL**

114 ± 42

114 ± 38

114 ± 40

0.621

TG, mg/dL**

194 ± 125

193 ± 116

194 ± 120

0.898

Hepatitis B*

2 (1.9)

4 (2.9)

6 (2.5)

0.465

Hepatitis C*

6 (5.7)

5 (3.7)

11 (4.5)

0.330

Medication history

Biochemical parameters

Hb: Haemoglobin, Cr: Creatinine, Ca: Calcium, P: Phosphorus, Alb: Albumin, PTH: Parathyroid hormone,
T. Sat: Transferrin saturation, Fer: Ferritin, CRP: C-Reactive protein, TC: Total cholesterol, LDL: Low density
lipoprotein, TG: Triglyceride, # P < 0.05, *n (%),** mean ± SD

patients underwent PD. Previous HD history were present
in 19% (n: 46) of the patients, and the mean period of HD
therapy prior to PD was 1 ± 2.9 years. Total follow-up
period was 23.958 patient months (2.178 patient years).
The mean dialysis duration was 4.3 ± 3.9 patient-years.
During the follow-up period, only 69 patients stayed on
PD, 68 patients died. Patients (22 of them) received renal
transplantation, 75 patients were permanently transferred
to HD, and 8 patients were lost to follow-up (Table 4).
3.3. Technique failure
PD catheter was removed from 64 patients (26.4%) due
to technique failure. Technique failure was not associated
with increased risk of mortality (P: 0.26). The main
causes of technique failure were PD-related infections
(54.6%) and mechanical complications (30.6%). There
were 297 episodes of peritonitis that occurred over the
total study period. The overall incidence of peritonitis
during the 9-year study period was 0.18 (ranging from
0 to 14.9) episodes per patient year which equals 1
peritonitis episode for every 7.3 patient-years or 1 episode
of 80.6 patient-months. Mechanical complications were

detected in 21.5% (n: 52) of the cases. The most common
mechanical complications in our PD patients were obesity,
hernia and drainage problem. Complications of PD were
given in Table 5.
3.4. Mortality
Of the patients 68 (28%) died, of which 8 (12.5%) were
early deaths. Infection was the most common cause of
mortality among our PD patients (29.4%) and followed by
cardiovascular diseases (Table 4).
According to univariate analysis; advanced age, low
systolic and diastolic blood pressure, the presence of
diabetes mellitus, glomerulonephritis, tubulointerstitial
nephritis, refractory heart failure, comorbidity,
malignancy, and cerebrovascular disease were predictors
of mortality (Table 1). Low albumin, Kt/V urea and
creatinine levels and high C-reactive protein levels were
significantly associated with a higher risk of mortality
(Table 2 and Table 3).
The following 4 clinical variables were selected
as independent risk factors for all-cause mortality by
multivariate analysis: age (HR, 1.1; 95% CI, 1.04–1.1),
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Table 3. Patients’ peritoneal dialysis related data.
Mortality group
(n: 68)

Survival group
(n: 174)

Total
(n: 242)

P

Previous HD history*

23 (21.7)

23 (16.9)

46 (19)

0.410

Automatic PD*

27 (25.5)

49 (36)

76 (31.4)

0.090

Anuria*

39 (57.4)

64 (47.1)

103 (50.5)

0.180

Urine V (mL)***

835 (325–2285)

845 (222–2650)

835 (222–2650)

0.810

Ultrafiltration V (mL)***

1500 (500–3500)

1500 (300–2800)

1500 (300–3500)

0.825

Icodextrin*

105 (94.1)

128 (99.1)

233 (96.3)

0.082

Nutrineal*

55 (52)

61 (45)

116 (47.9)

0.301

Low permeability* †

10 (9.4)

13 (9.6)

23 (9.5)

0.076

Kt/V urea**

2.03 ± 0.49

2.34 ± 0.74

2.24 ± 0.69

0.002#

RRF (mL/min/1.73 m2) ***

4 (2-6.2)

2.7 (0.2-16)

2.7 (0.2-16)

0.35

Technique survival (years)***

4.1 (0.6–18.3)

3.2 (0.1–22.3)

4.6 (0.1–22.3)

0.075

Peritonitis history*

77 (72.6)

65 (47.8)

142 (58.7)

0.003#

Tunnel infection*

5 (4.7)

4 (2.9)

9 (3.7)

0.348

Exit-site infection*

0 (0)

5 (3.7)

5 (2.1)

0.054

HD: Haemodialysis, PD: Peritoneal dialysis, V: Volume, Kt/V: Dialysis adequacy, RRF: Residual renal function, † The
data for 44 patients (18.2%) were missing, # P < 0.05, *n (%), ** mean ± SD, *** median (range).

diabetes mellitus, (HR, 2.5; 95% CI, 1.4–4.5), malignancy
(HR, 3.2; 95% CI, 1.3–7.6), refractory heart failure (HR, 8.3;
95% CI, 2.8–23.9). Advanced age, the presence of diabetes
mellitus, malignancy, and refractory heart failure also
increased mortality as independent risk factors (Table 6).
3.5. Technique and patient survival
The technique survival rates were 92.6%, 89%, 81.8%,
77.3%, and 67.6% at 1, 2, 3, 5 and 9 years, respectively
(Figure 1a). The mean technique survival was 14.1 ± 1.4
years (Table 7). The patient survival rates were 93.2%,
81.6%, 68.1%, and 45% at 1, 3, 5, and 9 years after PD
initiation, respectively (Figure 1b). The mean patient
survival was 10.8 ± 0.9 years (HR, 10.8 ± 0.9; 95% CI, 8.9–
12.7) (Table 7).
3.6. Upon data analysis of patients within subgroups
The patient survival rates were 91%, 81%, 65%, and 42% at
1, 3, 5, and 9 years, according to the PD time, respectively
(HR, mean 10.9 ± 1 years; 95% CI, 8.9–12.9). The patient
survival rates were 96%, 84%, 70%, and 43% at 1, 3, 5, and
9 years, after exclusion of early death, respectively (HR,
mean 11.1 ± 1 years; 95% CI, 9.1–13). The patient survival
rates were 94%, 83%, 69%, and 41% at 1, 3, 5, and 9 years,
after exclusion of patients who have prior HD history,
respectively (HR, mean 10.9 ± 1.1 years; 95% CI, 8.7–13.1).
Peritonitis group consisted 58.7% (n: 142) of all
patients. The number of peritonitis episodes were higher
in the mortality group compared to the survival group
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(72.6% vs 47.8%, P: 0.003) (Table 3). According to Kaplan
Meier survival analysis, no significant difference was
observed in the survival rates and survival time between
the peritonitis-free and peritonitis groups (mean 10.9 ±
1.2 vs 7.9 ± 0.9 years, P: 0.715) (Figure 2a).
Mortality was higher in diabetic group compared
to nondiabetic group (45.3 vs 18.4, P = 0.00) (Table 1).
Patient survival time in diabetic group was lower than that
of nondiabetic group (mean 5.5 ± 0.7 vs 12.9 ± 1.3 years,
P = 0.00) (Table 7). Patient survival rates in diabetic group
compared to non-diabetic group were found to be 88.4%
vs 96.3%, 64% vs 88.9%, 36.8% vs 79.8%, and 16.4% vs 53%
in –1, –3, –5, and –9 years, respectively (Figure 2b).
Mortality was higher in comorbidity group compared
to non-comorbidity group (87.7% vs 63.2%, P = 0.00)
(Table 1). Patient survival time in comorbidity group was
lower than that of non-comorbidity group (mean 7.6 ± 0.6
vs 12.9 ± 1.2 years, P = 0.00) (Table 7). Patient survival
rates in comorbidity group compared to noncomorbidity
group were found to be 91.9% vs 94.4%, 76.8% vs 94.4%,
59.2% vs 86.5%, 31.3% vs 74% in –1, –3, –5, and –9 years,
respectively (Figure 2c).
Mortality was lower in patients younger than 40 years
of age and higher in patients older than 65 years of age
(21.8% vs 71.1%, P = 0.00). The survival time was lower
in patients older than 65 years of age compared to patients
younger than 40 years of age (mean 3.7 ± 0.5 vs 19.1 ± 1.5
years, P = 0.00) (Table 7). There was a significant difference
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Table 4. Long-term results of peritoneal dialysis patients.
PD follow-up time (years)**

4.3 ± 3.9

Mortality rate*

68 (28.1)

Early mortality rate*

8 (3.3)

Patient survival (years)**

3.8 ± 2.9

Technical failure rate*

64 (26.4)

Technical survival (years)***

4.6 (0.1–22.3)

Drop-out causes in PD patients (n: 75)
PD-related infections*

41 (54.6)

Mechanical complications*

23 (30.6)

Patients preference*

2 (2.6)

Unknown*

9 (12)

Final status of the patients
Stayed on PD*

69 (28.5)

Died during the study*

68 (28)

Received renal transplantation*

22 (9)

Transferred to haemodialysis*

75 (31)

Loss to follow-up*

8 (3.3)

The causes of death
Unknown*

22 (32.3)

Infection*

20 (29.4)

Cardiovascular disease*

15 (22)

Malignancy*

5 (7.3)

Cerebrovascular disease*

5 (7.3)

Others*

1 (1.4)

PD: Peritoneal dialysis, *n (%), ** mean ± SD, *** median (range).

in the Kaplan–Meier survival between the different age
range: the group aged >65 years had the worst survival
rates compared with the 2 groups (aged <40 years and ≥40
years and <65 years) (Figure 2d).
4. Discussion
PD treatment was started in our medical centre for the first
time on September 1st of 1998. Over the 9-year period,
which this study covers, the total number of patients who
commenced renal replacement therapy were 2084 at our
hospital. Amongst 2084 patients, 1656 of them underwent
HD, 242 of them underwent PD and 186 received renal
transplantation. This is the first study to investigate long
term outcomes and all-cause of mortality in PD patients
in our centre.
The mean age of our patients was similar to that
reported in other studies (52.5 vs. 43.9– 62.7 years)
[8,18,19]. Unlike other studies, the rate of our elderly

Table 5. Complications related with peritoneal dialysis.
1. PD-related infections*

41 (16.9)

Peritonitis
Peritonitis history*

142 (58.7)

Peritonitis episodes (3 or more) *

50 (20.7)

Total number of peritonitis attacks (n)

297

Peritonitis rate (episodes per patients-year)*** 0.18 (0–14.9)
Tunnel infection*

9 (3.7)

Exit-site of infection*

5 (2.1)

2. Mechanical complications*

52 (21.4)

Obesity*

79 (32.6)

Hernia*

18 (7.4)

Drainage problem*

17 (7.0)

Ultrafiltration failure*

6 (2.5)

Dialysis failure*

5 (2.5)

Encapsulated sclerosing peritonitis*

3 (1.2)

Dialysate leakage*

2 (0.8)

Ileus*

1 (0.4)

PD: Peritoneal dialysis, *n (%), *** median (range).

patients was higher than other studies (24.4% vs. 10.4%–
15.8%) [17,18] and female participants were the majority
in our patients (59.3%–63.8% vs 47.5% male) [8,18]. The
mean dialysis duration in our patients was longer than
other studies (51.6 vs. 27.7–33 months) [8,18]. Compared
with other studies, our patients had similar rates of diabetes
(24.2%–48.4% vs 30.2%) [4,18,19]. PD offers an alternative
treatment option in refractory heart failure and reduces
the incidence of decompensation attacks [20]. We had 10
patients (4.1%) who underwent PD due to refractory heart
failure. The incidence of tuberculosis in PD patients was
reported as 15% in a study from India [9]. In our study, the
incidence of tuberculosis was lower (4.1%). Approximately
30%–50% of all PD patients in the worldwide and 22% of
all PD patients in our country prefer APD as PD modality
[8,12,18,19,21,22]. This rate was similar in our cases.
Peritonitis was seen as the cause of technique failure
in 16.9% of our patients. It was similar to the rates
reported in the literature (20.7%–42.6%) [14,19,21]. The
prevalence of mechanical complications in our series was
lower compared with the different series published in the
literature (21.5% vs. 31.2%–36.8%) [4,8].
In different studies, the mortality rate of PD patients
has been reported to be 10%–28% [3,8,18,23]. Mortality
rate of our PD patients at the end of the 9 years period
was 28%, in the same range as other studies but on the
higher end. The major cause of mortality in our patients
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Table 6. Multivariate cox regression analysis of patient mortality.
B

SE

Wald

df

p

HR

Age (years)

0.067

0.012

29.72

1

0.0001

Diabetes mellitus

0.90

0.30

9.14

1

Malignancy

1.16

0.44

6.95

1

Refractory heart failure

2.11

0.54

15.04

1

95.0% CI for HR
Lower

Upper

1.1

1.04

1.11

0.02

2.50

1.40

4.50

0.008#

3.2

1.3

7.6

0.000

8.3

2.8

23.9

#

#

#

SE: Standard Error, CI: Confidence interval, HR: Hazard ratio, # P < 0.05.

Figure 1. a: Kaplan-Meier curve for overall technique survival of the peritoneal
dialysis patients, b: Kaplan-Meier curve for overall survival of peritoneal dialysis
patients
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Figure 2. a: Kaplan-Meier curve for survival, peritonitis group vs peritonitis-free
group (P = X by log-rank), b: Kaplan-Meier curve for survival, diabetic group
vs nondiabetic group, c: Kaplan-Meier curve for survival, comorbidity group vs
noncomorbidity group, d: Kaplan-Meier curve for survival, age groups <45 vs
between 45–65, vs >65.

was infection (29,4%), followed by cardiovascular diseases
(22%). Although rates varied from our results, the same
reasons were reported in the other studies. In some
studies, cardiovascular diseases were shown to be the most
common cause of death (39%–60%), infectious causes
were the second most common cause of death (17.6%–
40%) among PD patients [8,9,14,17,19,23,24].
The rate of PD survivors was reported to be 58.9% in a
6-year study from Japan [18] and %46.3 in a 2-year study

from China [23]. We found the rate of PD survivors to
be lower (28.5%), in the 9-year follow-up period. Maybe
we can explain this with a longer follow-up period than
others. Comparing with the other study patients our rate
of transferred to haemodialysis (30.9% vs 8.4%–29.4%)
and renal transplantation (9% vs. 1.6%–39%) were similar
[10,18,19,23].
Just as reported in literature, advanced age was found
to be an independent risk factor that increases the risk
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Figure 2. (Continued).

of mortality [17,18,24,25]. In one study, male sex was
reported as a risk factor for mortality, and similar to our
study, some studies reported that sex did not play a role
in mortality [18,24,25]. Although high BMI was shown to
reduce all-cause mortality in one study, no relationship was
found between BMI and mortality in our study [26]. One
study showed a significant relationship between mortality
and previous HD history in PD patients [24]. However,
our study did not show any difference.
Although PD modality was found to be significant
in terms of mortality in one study, most studies did not
show any difference between CAPD and APD in mortality
[17,19,22,24]. In our study, no significant difference was
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found between 2 groups in terms of mortality. In our
study, as in other similar studies, the risk of mortality was
significantly higher in patients with diabetes mellitus,
cardiovascular disease and comorbidity [17,18,24,25].
As also stated in other studies, low serum creatinine
level and hypoalbuminemia were found to be risk factors
for all-cause mortality in our study [14,17,18,25]. High
C-reactive protein was found to be a significant risk factor
in our study, as reported in one other study [18]. Although
it has been reported in some studies, no correlation was
found between phosphorus level and mortality in our
study [18,25]. Though some studies have reported that
high cholesterol and low HDL are risk factors for mortality
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Table 7. Patient and technique survival analysis, and comparison of survival analysis according to various
subgroups.

EMa

SE

Patient sur

10.8

Technique sur

14.1

95% CI

1.year† 3.year† 5.year† 9.year†

LB

UB

0.98

8.9

12.7

93.2

81.6

68.1

45.0

1.4

11.2

16.8

92.6

81.8

77.3

67.6

Age

p

<40

19.1

1.5

16.1

22.1

95.0

95.0

95.0

88.2

40–65

7.2

0.5

6.3

8.1

97.0

85.4

70.6

34.4

>65

3.7

0.5

2.7

4. 7

75.6

52.4

24.0

0.48

Female

9.4

1.0

7.4

11.4

93.8

87.1

70.4

40.9

Male

12.0

1.3

9.5

14.5

91.5

76.4

65.1

44.2

Yes

10.9

1.2

8.7

13.2

94

81

66

45

No

7. 9

0.9

6.2

9.5

89

81

68

32

Yes

5.5

0.7

4.1

6.9

88.4

64

36.8

16.4

No

12.9

1.3

10.4

15.4

96.3

88.9

79.8

53.0

Yes

7.6

0.6

6.5

8.8

91.9

76.8

59.2

31.3

No

12.9

1.2

10.7

15.2

94.4

94.4

86.5

74.0

0.000#

Sex
0.702

Peritonitis history
0.715

Diabetes mellitus
0.000#

Comorbidity
0.000#

Sur: Survival, EM: Estimate mean, SE: Standard error, CI: Confidence interval, LB: Lower bound, UB: Upper
bound, †Survivor %, # P < 0.05

in PD patients, there was no correlation between lipid
levels and mortality in our patients [18,25].
In our study, anuria and urine volume were not seen
as risk factors for mortality. Contrary to our study, the
relationship between low urine volume and mortality was
reported in previous studies [17]. In one study, low RRF
was reported as an independent risk factor that worsened
patient survival rates [19]. In our study, RRF was not
found as a risk factor for mortality. As also was found
in another study, low Kt/V was found to be a risk factor
for mortality in our study [25]. The role of peritoneal
transport characteristics on mortality is controversial [27].
In our study, no correlation was found between membrane
transport characteristics and mortality.
In the literature, peritonitis history was shown to be an
independent risk factor for all-cause mortality [9,17,23].
Similarly, we found an increased risk of mortality in
peritonitis group compared to the nonperitonitis group.
There was no difference between the peritonitis group
and the nonperitonitis group in terms of patient survival
in our study, similar to what was reported by Lasfar et
al [8]. The International Society for Peritoneal Dialysis

Guidelines considers the peritonitis rate of 0.67 per year
to be acceptable [8,16]. But the incidence of peritonitis
varies greatly from unit to unit. The reported peritonitis
rates were 0.16–0.44 per patient year [8,18,23]. Similarly,
this rate was 0.18 (0–14.9) attacks per patient year in
our study. Indeed, this peritonitis rate in our centre (one
every episode 80.6 patient-months) was higher than those
reported in previous studies. In some studies, the overall
peritonitis rate was 1 episode per 25–47.3 patient-months
[6,8,19]. This may be due to differences in personal hygiene
and self-care between patients and the education strategy
of the center.
Technique failure rates were reported 31%–38.9% in
previous studies [6,14,19]. This rate was lower in our study
(26.4%). In other studies, different technique survival rates
such as 87.9%–97.9% and 60.4%–84.5% were reported in
the –1 and –3 years, respectively [8,14,17]. Our technique
survival rates (92.6%, 81.8%, for –1 and –3 years,
respectively) were similar to these studies. The reported
mean technique survival was (61.7 ± 5.2 months) very
close to our results (60 ± 55.2 months) [17]. PD-related
infections are reported to be the most important factor
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for technique failure in PD patients [3,5,8–10,15,17,24].
In our series too, the most common cause of technique
failure was infections. It causes patients to permanently
transfer from PD to HD [15]. As reported in one study,
technique failure had no effect on the mortality of our PD
patients [10].
Rates of survival across our patients were similar to
those observed in other studies (92.2% to 96.1% vs. 93.2%,
74.2% to 91.4% vs. 81.6%, and 57% to 89.3% vs %68.1, –1,
–3, and –5 years, respectively) [8,14,19]. Compared with
another study from Turkey, the mean survival rates of our
elderly PD patients were 78.8% vs. 75.6% and 50.9% vs.
52.4% at 1 and 3 years, respectively [17]. The mean survival
time of our elderly PD patients was similar to a study by
Sakacı et al (44.4 vs 38.9 months) [17].
The majority of reports agree that patient survival is
lower in diabetics compared to nondiabetics [8,18,19].
In this study, the survival was inferior and mortality was
higher in diabetics compared to nondiabetics. As also seen
in other studies, the survival was inferior and mortality
was higher in the group aged ≥65 years compared to the
2 groups (aged <40 years and ≥40 years and <65 years) in
our study [8,19].
In summary, in this study we found that, advanced
age, the presence of diabetes mellitus, malignancy, and
refractory heart failure increased mortality as independent
risk factors. Diabetic patients, patients with comorbidity,

and patients older than 65 years were the most important
factors associated with mortality and patient survival.
Although peritonitis increased the risk of mortality in our
patients, it seemed to have no significant effect on patient
survival.
In conclusion, when beginning PD, patients with
advanced age and presence of comorbidity (especially who
have diabetes, malignancy, and refractory heart failure)
should be marked for close follow up in order to have
better long-term outcomes. Although peritonitis is the
most feared complication of PD, our study showed that
peritonitis did not reduce patient survival. The strengths
of this study include its larger sample size and long followup time. This is the first study to define 9-year mortality
predictors in PD patients in our centre.
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